The short interest in Hims & Hers Health (NYSE:HIMS) has approached critical levels, financial data provider S3 Partners said ...

Health and wellness company Hims & Hers, which sells alternatives to weight-loss drugs like Wegovy, is now collaborating with ...

Shares of Hims & Hers Health ( HIMS -5.48%) and LifeMD ( LFMD -14.33%) are surging on Tuesday. The companie' stocks had ...

Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

Shares in Hims & Hers Health soared in early-morning trading after it announced a partnership with Wegovy maker Novo Nordisk.

Hims & Hers is an increasingly profitable, vertically integrated telehealth platform with major tailwinds, positioning it as ...

Pharma giant Novo Nordisk is partnering with telehealth companies to expand access to its blockbuster weight loss drug Wegovy ...

Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. | Novo Nordisk appears to be ...

The drugmaker is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy ...

Overall, though, we'd argue that HIMS's stock is in a great position to sell puts on. At this price, the options pay a ...

In essence, Hims & Hers is embracing a "if you can't beat 'em, join 'em" approach that gives their customers more options.